Nmdae is named as an intervention in 6 current clinical trials in our China register. 6 are recruiting patients now. All registered phases are Phase 2. The lead sponsor is China Medical University Hospital. The most-studied condition is Schizophrenia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
NMDA Modulation in Major Depressive Disorder
NCT04637620 · ClinicalTrials.gov ↗ · Major Depressive Disorder
|
Phase 2 | Recruiting | China Medical University Hospital | China |
|
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
NCT04917302 · ClinicalTrials.gov ↗ · Schizophrenia
|
Phase 2 | Recruiting | China Medical University Hospital | China |
|
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
NCT05052853 · ClinicalTrials.gov ↗ · Prodromal Schizophrenia
|
Phase 2 | Recruiting | China Medical University Hospital | China |
|
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
NCT05136755 · ClinicalTrials.gov ↗ · Major Depressive Disorder
|
Phase 2 | Recruiting | China Medical University Hospital | China |
|
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
NCT06021197 · ClinicalTrials.gov ↗ · Schizophrenia
|
Phase 2 | Recruiting | China Medical University Hospital | China |
|
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
NCT06574360 · ClinicalTrials.gov ↗ · Schizophrenia
|
Phase 2 | Recruiting | China Medical University Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| China Medical University Hospital | 6 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 6 | 6 |
A trial with sites in more than one country appears in each of those registers.
6 current trials in our China register name Nmdae as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of the 6 trials are recruiting: 6 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is China Medical University Hospital. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nmdae works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nmdae works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nmdae (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.